Evidence map›Paper›PMID 37177745›Full record

ArticleSensors (Basel, Switzerland)2023

Miniaturization of an Osmotic Pressure-Based Glucose Sensor for Continuous Intraperitoneal and Subcutaneous Glucose Monitoring by Means of Nanotechnology.

Andreas Pfützner, Barbora Tencer, Boris Stamm, Mandar Mehta, Preeti Sharma, Rustam Gilyazev, Hendrick Jensch, Nicole Thomé, Michael Huth

Open access · goldAbstract read
In one paragraph

Article in Sensors (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Andreas PfütznerLifecare AS, 5058 Bergen, Norway.ORCID 0000-0003-2385-0887
Barbora TencerLifecare AS, 5058 Bergen, Norway.
Boris StammLifecare Nanobiosensors GmbH, 55128 Mainz, Germany.
Mandar MehtaLifecare Nanobiosensors GmbH, 55128 Mainz, Germany.
Preeti SharmaLifecare Nanobiosensors GmbH, 55128 Mainz, Germany.
Rustam GilyazevLifecare Nanobiosensors GmbH, 55128 Mainz, Germany.
Hendrick JenschLifecare Laboratories GmbH, 55128 Mainz, Germany.
Nicole ThoméLifecare Laboratories GmbH, 55128 Mainz, Germany.
Michael HuthInstitute of Physics, Goethe-Universität, 60323 Frankfurt am Main, Germany.ORCID 0000-0001-7415-465X
Goethe University Frankfurt · DEUniversity of Applied Sciences Mainz · DE

Funding

EU Horizon 2020 Grant Program 951933 (FORGETDIABETES)Lifecare AS, Bergen, Norway R&D Grant
6 · The paper itself

Abstract

The Sencell sensor uses glucose-induced changes in an osmotic pressure chamber for continuous glucose measurement. A final device shall have the size of a grain of rice. The size limiting factor is the piezo-resistive pressure transducers inside the core sensor technology (resulting chamber volume: 70 µL. To achieve the necessary miniaturization, these pressure transducers were replaced by small (4000 × 400 × 150 nm³) nano-granular tunneling resistive (NTR) pressure sensors (chamber volume: 750 nL). For benchmark testing, we filled the miniaturized chamber with bovine serum albumin (BSA, 1 mM) and exposed it repeatedly to distilled water followed by 1 mM BSA solution. Thereafter, we manufactured sensors with glucose testing chemistry (ConcanavalinA/dextran) and investigated sensor performance with dynamic glucose changes between 0 and 300 mg/dL. Evaluation of the miniaturized sensors resulted in reliable pressure changes, both in the BSA benchmark experiment (30-35 mBar) and in the dynamic in vitro continuous glucose test (40-50 mBar). These pressure results were comparable to similar experiments with the previous larger in vitro sensors (30-50 mBar). In conclusion, the NTR pressure sensor technology was successfully employed to reduce the size of the core osmotic pressure chamber by more than 95% without loss in the osmotic pressure signal.

Indexed as

Biosensing TechniquesBlood GlucoseBlood Glucose Self-MonitoringGlucoseMiniaturizationNanotechnologyOsmotic PressureBlood GlucoseGlucosecontinuous glucose monitoringFEBIDimplantable glucose sensorNTR sensorosmotic pressure

Identifiers

PMID37177745
PMCPMC10181718
OpenAlexW4376630601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.